270 related articles for article (PubMed ID: 26563196)
1. Oral Targeted Therapies and Central Nervous System (CNS) Metastases.
Gabay MP; Wirth SM; Stachnik JM; Overley CL; Long KE; Bressler LR; Villano JL
CNS Drugs; 2015 Nov; 29(11):935-52. PubMed ID: 26563196
[TBL] [Abstract][Full Text] [Related]
2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in brain metastasis.
Soffietti R; Trevisan E; Rudà R
Curr Opin Oncol; 2012 Nov; 24(6):679-86. PubMed ID: 22820413
[TBL] [Abstract][Full Text] [Related]
4. Specialty pharmacy services for patients receiving oral medications for solid tumors.
Stein J; Mann J
Am J Health Syst Pharm; 2016 Jun; 73(11):775-96. PubMed ID: 27126828
[TBL] [Abstract][Full Text] [Related]
5. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
6. [Systemic treatment of brain metastases from lung cancer].
Barlesi F; Spano JP; Cortot AB; Carpentier AF; Robinet G; Besse B
Cancer Radiother; 2015 Feb; 19(1):43-7. PubMed ID: 25656857
[TBL] [Abstract][Full Text] [Related]
7. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
8. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapties for the Treatment of Adults With Metastatic Brain Tumors.
Elder JB; Nahed BV; Linskey ME; Olson JJ
Neurosurgery; 2019 Mar; 84(3):E201-E203. PubMed ID: 30629215
[TBL] [Abstract][Full Text] [Related]
9. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy and the treatment of brain metastases.
Peak S; Abrey LE
Hematol Oncol Clin North Am; 2006 Dec; 20(6):1287-95. PubMed ID: 17113463
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance.
Russo A; Franchina T; Ricciardi GR; Ferraro G; Scimone A; Bronte G; Russo A; Rolfo C; Adamo V
Expert Rev Anticancer Ther; 2016 Jun; 16(6):615-23. PubMed ID: 27109446
[TBL] [Abstract][Full Text] [Related]
14. The future of targeted therapies for brain metastases.
Berghoff AS; Preusser M
Future Oncol; 2015; 11(16):2315-27. PubMed ID: 26260810
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the role of molecular targeted therapies in patients with brain metastases.
Papadatos-Pastos D; Banerji U
J Neurooncol; 2011 Dec; 105(3):467-74. PubMed ID: 21785914
[TBL] [Abstract][Full Text] [Related]
16. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance.
Honeywell RJ; Kathmann I; Giovannetti E; Tibaldi C; Smit EF; Rovithi MN; Verheul HMW; Peters GJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182766
[No Abstract] [Full Text] [Related]
17. The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions.
Murrell J; Board R
Cancer Treat Rev; 2013 Dec; 39(8):833-8. PubMed ID: 23845462
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
19. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
[TBL] [Abstract][Full Text] [Related]
20. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
